Privileged scaffolds in medicinal chemistry : design, synthesis, evaluation /
One strategy to expedite the discovery of new drugs, a process that is somewhat slow and serendipitous, is the identification and use of privileged scaffolds. This book covers the history of the discovery and use of privileged scaffolds and addresses the various classes of these important molecular...
| Corporate Author: | |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
[Cambridge] :
Royal Society of Chemistry,
[2015]
|
| Series: | RSC drug discovery series.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Cover; Preface; Contents; Chapter 1 Privileged Scaffolds in Medicinal Chemistry: An Introduction; 1.1 Introduction; 1.2 The Privileged Scaffolds in Drug Discovery; 1.3 Conclusion; Acknowledgments; References; Chapter 2 Privileged Scaffolds in Medicinal Chemistry
- A Computational Approach; 2.1 Introduction; 2.2 Scope of the Study; 2.3 Privileged Scaffolds; 2.4 Molecular Docking; 2.5 Protein Structure Prediction; 2.5.1 Comparative Modeling; 2.5.2 Threading (Fold Recognition); 2.5.3 Model Building and Refinement; 2.5.4 Loop Modeling; 2.5.5 Side Chain Modeling; 2.5.6 Model Building
- 4.1.4 Natural Products Containing (Benz)imidazoles4.2 Case Studies of Marketed Drugs; 4.2.1 Angiotensin II Receptor Antagonists; 4.2.2 H+, K+-ATPase Inhibitors; 4.2.3 H1-antihistamines; 4.2.4 Anthelmintics; 4.2.5 Miscellaneous; References; Chapter 5 Pyrazoles; 5.1 General Remarks about Pyrazoles; 5.1.1 Physicochemical Properties of Pyrazoles; 5.1.2 Synthesis of Pyrazoles; 5.1.3 Natural Products Containing Pyrazoles; 5.2 (Former) Marketed Drugs; 5.2.1 Anti-inflammatory Drugs; 5.2.2 Vasodilators; 5.2.3 Tyrosine-kinase-inhibitors; 5.2.4 Cannabinoid-receptor-antagonists